Revenue was reported as $5.87 billion. Regeneron shares have dropped 11 percent since the beginning of the year, while the Standard & Poor's 500 index has stayed nearly flat. The stock has declined 6.5 percent in the last 12 months. This …
Yahoo!2mon
After posting better-than-expected first-quarter results, Regeneron Pharmaceuticals (NASDAQ: REGN) stock enjoyed a nice bounce. The biotech announced solid sales for eye-disease drug Eylea and a strong launch for atopic dermatitis …
After posting better-than-expected first-quarter results, Regeneron Pharmaceuticals (NASDAQ: REGN) stock enjoyed a nice bounce. The biotech announced solid sales for eye-disease drug Eylea and a strong launch for atopic dermatitis …
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's shareholders have been on a roller …